 I'm Tom Crelan, I'm a post-doctoral researcher here at the Machidon-Oxford Tropical Medicine Research Unit in Bangkok working in the Bacteria Resistance Analysis Group which is led by Ben Cooper. The group in general focuses on the transmission of bacterial pathogens mainly in hospital settings and looks for interventions to combat the spread of resistant organisms. My research focuses on a carriage study of multi-drug resistant bacteria from a children's hospital in Cambodia and what we aim to do is to establish risk factors for transmission and acquisition of the pathogens and also to model the impact of interventions to reduce the spread of antimicrobial resistance. So the work brings together epidemiological and genomic data, so that's patient-level data collected in the hospital by clinicians and sequenced data of the bacteria itself and what we aim to do is to use this data to reconstruct transmission networks, so who infected whom and that can lead to questions like what makes someone more likely to transmit a pathogen or what makes someone likely to spread it on to multiple people. Do we see evidence of super-spreading in these hospital settings, for instance? We've observed this in major outbreaks, so in viral pandemics such as Ebola and SARS we see this pattern, but it's not very well understood in hospital-acquired infections whether it's this pattern that's driving transmission or not. Certainly an early observation is that patients that stay the longest are the most likely to both acquire infections and pass them on to other people and we also want to explore the effect of a probiotic which was used when children arrived in the hospital to reduce the risk of acquiring infections and we need to quantify exactly how effective that was. Suspended-acquired infections are a major problem particularly in Southeast Asia where the prevalence of multi-drug resistant bacteria is extremely high. In the carriage study that we're working on we observe that almost all children become infected with multi-drug resistant bacteria during their stay. Over 6% of people arrive with multi-drug resistant organisms and the rest are generally colonised during their stay, so it's very very high prevalence and this leads to challenges in control and during clinical episodes it can be difficult to treat because it's been a resistant to so many antibiotics. In this region we face the challenge that people are generally wealthy enough to afford antibiotics but they may not be controlled by prescription so it leads to very high rates of antibiotic usage and this really drives resistance in this area. So being here in Bangkok we really have access to a lot of study sites in this region. These areas are both hotspots for antimicrobial resistance in hospitals and it's a major problem in this area but it's also understudied and it's challenging to get really good data from this region so through this through the oxotropical network we have very strong very strong links which aids in both sample collection and getting good data for analysis. Using data from these studies we can build say simulations or models that allow us to investigate the impact of different interventions. So if we can build simulations that effectively reconstruct the conditions of that hospital we can investigate the impact of interventions in a very low cost way and this can then allow us to decide what we think will be the best interventions to use and that will inform future clinical trials. We relay our results back to the clinicians in the hospitals that carried out these studies and they can make decisions based on our results and modify their clinical practice accordingly but also antimicrobial resistance is a global problem and although Southeast Asia is a major hotspot it's underrepresented in terms of data and research so our results are important in feeding into the global conversation and awareness about drug-resistant bacteria globally.